Kornimate/medical-research-clean huggingface dataset:
continuing medical education to improve knowledge of viral hepatitis b-c in primary healthcare workers

Conditions: Viral Hepatitis

Summary: the purpose of study is identifying the effectiveness of 'continuing medical education' (cme) to primary healthcare worker to improve knowledge about viral hepatitis b-c


Eligibility criteria:
inclusion criteria: * currently working at outpatient department, primary-level hospitals * having practicing certificate * not attending any long-term education * accepting icf exclusion criteria: * not attending the full number of lessons * not answering the questionnaire
a study to evaluate efficacy and safety of peginterferon alfa-2a (pegasys) and adeforvir dipivoxil (adv) in participants with lamivudine-resistant hepatitis b e antigen (hbeag)-positive chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: this study will evaluate the efficacy and safety of peginterferon alfa-2a or adv, in participants with lamivudine-resistant hbeag-positive chronic hepatitis b. participants will be randomized to receive either peginterferon alfa-2a for 48 weeks in combination with oral lamivudine for the first 12 weeks, or adv for 72 weeks in combination with oral lamivudine for the first 12 weeks. the anticipated time on study treatment is 72 weeks, and the target sample size is 255 individuals.


Eligibility criteria:
inclusion criteria: * adult participants 18-65 years of age * hepatitis b surface antigen (hbsag)-positive, hbeag-positive, and anti-hbs-negative for greater than or equal to (\>=) 6 months * receiving lamivudine currently, and for \>=6 months * hepatitis b virus (hbv)-deoxyribonucleic acid (dna) decreased \>=2 log during lamivudine treatment on \>=1 occasion * absence of cirrhosis confirmed by liver biopsy in previous 6 months exclusion criteria: * other drugs with activity against hbv within the prior 6 months, except lamivudine * antiviral, anti-neoplastic, or immunomodulatory therapy less than or equal to (\<=) 6 months before study - active infection with hepatitis a, c, or d virus, or human immunodeficiency virus * decompensated liver disease * medical condition associated with another chronic liver disease
statins and lupus: effects of statins on clinical lupus parameters, serological markers and toll-like receptors

Conditions: Systemic Lupus Erythematosus

Summary: this is an open label pilot clinical trial on a cohort of 15 lupus patients from the center for rheumatic disease. clinical evaluations and laboratory tests will be done and then if eligible, the patients will receive oral atorvastatin, at a fixed dose of 40mg/day. statins have been shown to induce clinical improvement in rheumatoid arthritis patients, as well as lupus patients. the effectiveness has been noted within 8 to 14 days, we will do our study for 3 months. clinical and laboratory tests will be checked at the 1 and 3 month interval. we hypothesize that statin drugs (atorvastatin) slow the progression of sle(systemic lupus erythematosus) disease activity and down regulates tlr(toll-like receptors) 2,4,and 9 pathways in addition to lowering lipid levels.

atorvastin (lipitor) is a commonly used drug approved by the fda for treatment of dyslipidemias. it is a relatively safe drug to use with periodic monitoring. eligibility critera: * age 18-60, females, as a marjority of lupus patients are female * at least 4 acr (american college of rheumatology) criteria of sle(systemic lupus erythematosus) * moderate to severe disease activity using approved sledai(systemic lupus erythematosus disease activity index) * ldl cholesterol 100-190mg/dl exclusion criteria: * pregnancy, and or lactating or wants to get pregnant * unable to take atorvastatin due to allergy, liver disease, elevated liver functions, myositis, or elvated cpk(creatine phosphakinase) * already on lipid lowering therapy * already on amiodarone, clarithromycin, cyclosporin, erythromycin, itraconazole, ketoconazole, nefazodone, verapamil, protease inhibitors, niacin, digoxin,k cholestyramine, colestipol * has a dianosis of myositis. our goal is to colledt preliminary data to see if there is a trend for the efficacy of atorvastatin in ameliorating sle disease activity and to evaluate tlrs(toll-like receptor) in sle patients. a p value of \<0.05 will be considered statistically significant. our baseline and at subsequent visits, we will have 80% power to detect a minimum of 34%-39% difference for most of the continous variables measured at different intervals.

Eligibility criteria:
inclusion criteria: * age 18-60, female * have at least four acr criteria for sle * sledai score \> 4 * ldl cholesterol level from 100-190mg/dl exclusion criteria: * pregnant, lactating, or wanting to become pregnant * unable to take atorvastatin due to allergy, liver disease, elevated lever function test, myositis, or eleveated cpk * already on lipid lowering therapy * participating in another lupus study * on drugs such as: amiodarone, clarithromycin, clclosporine, erythromycin, itraconazole, ketoconazole, nefazodone, verapamil, protease inhibitors, niacin, digoxin, cholestryrmine, colestipol * has a diagnosis of myositis

Keywords: lupus tlr's hyperlipidemia age eighteen to sixty female with sle sledai, greater than four ldl cholesterol elevated
in-vivo behavior of asqelio monofocal biaspheric intraocular lens

Conditions: Cataract; Intraocular Lens Complication

Summary: this is a study to evaluate the 24 month postoperative incidence and intensity of posterior capsular opacity in patients submitted to cataract surgery and implanted with a hydrophobic monofocal iol.

this study is a two-arm masked clinical evaluation study of incidence of pco after successful bilateral cataract surgery with implantation of a monofocal iol. subjects will be assessed 24 months after iol implantation. clinical evaluations will include incidence of adverse events, patient satisfaction questionnaire, as well as measurements of visual performance, optical quality, presence and intensity of pco, presence and intensity of iol glistening.

Eligibility criteria:
inclusion criteria: * subjects 22 years or older submitted to cataract surgery in at least 1 eye and implanted with asqelio monofocal or clareon monofocal iol exclusion criteria: * any pathology reducing potential best-corrected visual acuity beyond 0.30 logmar, including amblyopia, severe corneal dystrophy, diabetic retinopathy, extremely shallow anterior chamber, microphthalmos, retinal detachment, severe recurrent anterior or posterior segment inflammation of unknown ethiology, iris neovascularization, uncontrolled glaucoma, clinically significant macular degeneration, or pseudoexfoliation diagnosis. * previous ocular surgery * rubella * surgery motivated by traumatic cataract * ocular trauma or refractive surgery * any other systemic or ocular condition that, in the investigator's opinion, should exclude the subject from study * requiring additional procedures due to intraoperatory complications, mechanical or surgical interventions for manipulating the pupil, excessive iris movility, significant vitreous loss, significant, anterior chamber hyphema, capsular annular breakage, or any other unrecognized ocular conditions that might compromise iol positioning, as well as impossibility of locate the iol in the capsular bag due to surgical complications.

Keywords: posterior capsule opacitication incidence
acupuncture in osteoarthritis of the knee

Conditions: Osteoarthritis of the Knee

Summary: the aim of this study was to evalute three different acupuncture techniques, including one sham control, in its effect on osteoarthitis of the knee

background: acupuncture is one of the most frequently used complementary therapeutic approaches in the treatment of osteoarthritis of the knee. due to methodological shortcomings of previous randomized controlled studies, controversy persists whether the observed effects are specific to acupuncture or non-specific consequences of needling. objective: to compare classical chinese acupuncture, semi-standardized modern acupuncture and non-specific needling by means of a double-blinded repeated measures cross-over design. intervention: within three weeks all patients receive three treatment modalities in a random order in a double-blind study design. main outcome measures: improvement in knee flexibility according to the neutral-zero method, defining a success as improvement by 10 degrees or more. secondary parameter: improvement in pain according to the reduced womac score by 50 percent or more.

Eligibility criteria:
inclusion criteria: * patients above age 35 * knee osteoarthritis grade ii or iii according to the kellgren classification. exclusion criteria: * orthopedic deformations of the knee, * malignant disease * auto-immune disorders * surgery including arthroscopy during the past 12 months * pain medication with steroids * physical therapy or acupuncture within the last for weeks * no or a pain medication in continuous dosage

Keywords: acupuncture double-blind sham control osteoarthritis pain
ru anti-sars-cov-2 (covid-19) mabs in healthy volunteers

Conditions: Covid19

Summary: this is a first-in-human, open label, single dose, dose-escalation phase 1 study to evaluate the safety and pharmacokinetics of a combination of two highly neutralizing anti-sars-cov-2 mabs targeting two distinct epitopes on the receptor protein binding domain (rbd) of the sars-cov-2 spike protein in healthy volunteers.

the study has a standard 3+3 phase 1 dose escalation design. study participants will receive subcutaneous injections of c144-ls and c135-ls at 4ml (approximately 100mg of each antibody administered separately) or 8ml (approximately 200mg of each antibody administered separately), or sequential intravenous infusions of c144-ls and c135-ls, at one of three increasing dose levels (1.5 mg/kg, 5 mg/kg and 15 mg/kg of each antibody).

Eligibility criteria:
inclusion criteria: * aged 18 or older. * if sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use one effective method of contraception from 10 days prior to the antibody administration until 6 months after investigational product (ip) administration. exclusion criteria: * weight \> 110 kg for groups s1 and s2 only * history of prior positive sars-cov-2 rt-pcr or sars-cov-2 serology. * active respiratory or non-respiratory symptoms consistent with covid-19. * medically attended acute illness or hospitalization (ie, \>24 hours) for any reason within 30 days prior to screening. * acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease \[copd\], asthma exacerbations, or uncontrolled hypertension, as defined by a systolic blood pressure \> 180 and/or diastolic blood pressure \> 120, in the presence or absence of anti-hypertensive medications) in the past 6 months prior to screening. * use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months. * other clinically significant acute or chronic medical condition that in the opinion of the investigator would preclude participation. * laboratory abnormalities in the parameters listed: * absolute neutrophil count less than 1,500 k/mcl; * hemoglobin less than 10.5 gm/dl if female; less than 11 gm/dl if male; * platelet count less than 125,000 k/mcl; * alt less than 1.25 x uln; ast less than 1.25 x uln; * total bilirubin less than 1.25 x uln; * creatinine less than 1.1 x uln; * pregnancy or lactation. * any vaccination within 14 days prior to sars-cov-2 mabs administration (except influenza vaccine). * history of prior receipt of any sars-cov-2 vaccine or antibodies, including convalescent plasma. * known allergy/sensitivity or any hypersensitivity to components of the investigational agents. * history of severe reaction to a vaccine or monoclonal antibody administration or history of severe allergic reactions. * participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

Keywords: monoclonal antibody sars-cov-2
multisensory environment stimulation therapy on postural control in cerebral palsy

Conditions: Cerebral Palsy

Summary: to investigate the effect of multisensory environment stimulation therapy on postural control in spastic hemiplegic cerebral palsy.

fortypatients with spastic hemiplegic cerebral palsy will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the selected exercise program and the study group received the same exercise training program in addition to multisensory environment stimulation therapy, three times per week for three months. the evaluation methods are biodex, the pediatric balance scale, and multidirection reach test

Eligibility criteria:
inclusion criteria: * - forty children with cerebral palsy, * age will range as (9:12) years old * spastic hemiplegic cerebral palsy * normal body mass index standardmore than 50th and less than 85th for age and sex compared to standard egyptian growth charts adopted by the faculty of medicine, cairo university and national research centre. * gross motor function classification system: level i\&ii exclusion criteria: * • difficulty to communicate or to understand program instructions * any other neurological deficits or orthopaedic abnormalities, * secondary musculoskeletal complication * vestibular problems
impact of the time of oral nutritional supplements (ons) consumption on daily alimentary intakes of malnourished elderly

Conditions: Malnutrition in the Elderly

Summary: malnutrition is a severe comorbidity in hospitalised patients, especially in elderly. the consumption of oral nutritional supplements (nos) is one of several tools for fighting against malnutrition. their use is easy, and framed by recent french recommendations suggesting to propose nos at end of meals or as snacking . nevertheless, there is no scientific data to affirm which is the best of these two hypothesis in elderly hospitalised in long term care unit(ltcu) . moreover, a preliminary survey of nos consumption in ltcu in limoges university hospital showed some problems about the mode of supplying nos, partially linked with an insufficiency for paramedical staff in realizing importance of nos. however, the effect of time of supplying nos on total food consumption had not been evaluated in this first study. the new one will include 48 malnourished elderly patients in two ltcu and having a prescription of nos. they will receive them at the same quantity during the whole study either firstly at end of meals (10 days) and secondly as snackings (10 days), or conversely. order of choice will be randomised. total daily alimentary intakes will be noted by paramedical staff of the two units, and translated by dieticians in daily energy, protein, carbohydrates and lipids intakes. the time of supplying nos will be confronted with these intakes, in order to precise the best one.

malnutrition is a severe comorbidity in hospitalised patients, especially in elderly. the consumption of oral nutritional supplements (nos) is one of several tools for fighting against malnutrition. their use is easy, and framed by recent french recommendations suggesting to propose nos at end of meals or as snacking . nevertheless, there is no scientific data to affirm which is the best of these two hypothesis in elderly hospitalised in long term care unit(ltcu) . moreover, a preliminary survey of nos consumption in ltcu in limoges university hospital showed some problems about the mode of supplying nos, partially linked with an insufficiency for paramedical staff in realizing importance of nos. however, the effect of time of supplying nos on total food consumption had not been evaluated in this first study. the new one will include 48 malnourished elderly patients in two ltcu and having a prescription of nos. they will receive them at the same quantity during the whole study either firstly at end of meals (10 days) and secondly as snackings (10 days), or conversely. order of choice will be randomised. total daily alimentary intakes will be noted by paramedical staff of the two units, and translated by dieticians in daily energy, protein, carbohydrates and lipids intakes. the time of supplying nos will be confronted with these intakes, in order to precise the best one.

Eligibility criteria:
inclusion criteria: * malnourished elderly (age \>=70 y) hospitalised in ltcu * having a nos medical prescription o exclusion criteria: * non malnourished patients in ltcu, * age \<70.
dasatinib in imatinib resistant/intolerant chinese cml (chronic and advanced phase) subjects

Conditions: Leukemia

Summary: the primary objective of this study is to estimate the major cytogenetic response (mcyr) rate to dasatinib in subjects with cp cml, complete and overall hematologic response (chr and ohr) rate in subjects with ad cml or ph+ all who have primary or acquired resistance to imatinib, or are intolerant of imatinib, when administered at 100 mg qd (chronic cml) or 70mg bid (ap cml and ph+all).


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * signed written informed consent * men and women, ages 18 years of age or older * subjects with chronic phase (cp) or advanced disease (ad) chronic myeloid leukemia (cml)/ph+ acute lymphoblastic leukemia (ph+ all) * subjects resistant/intolerant to imatinib * subjects presenting: 1. eastern cooperative oncology group (ecog) performance status (ps) score 0-2 2. adequate hepatic function 3. adequate renal function 4. sodium, potassium, magnesium, phosphorus, calcium higher or equal than the lower limit of normal range exclusion criteria: * women of child bearing potential who are not using adequate birth control * women who are pregnant or breastfeeding * subjects eligible for stem cell transplantation * serious uncontrolled medical disorder or active infection * uncontrolled or significant cardiovascular disease * concurrent incurable malignancy other than cml * subjects who received imatinib, interferon, cytarabine within 7 days or other antineoplastic agents other than hydroxyurea within 14 days before dasatinib, dasatinib in the past * history of significant bleeding unrelated to cml

Keywords: chronic phase, advanced phase chronic myeloid leukemia philadelphia chromosome positive acute lymphoblastic leukemia
genetic and morphological analysis of thyrotoxic periodic paralysis

Conditions: Thyrotoxic Periodic Paralysis

Summary: the study aims to analyze the genetic variance between thyrotoxic periodic paralysis (tpp) patients and pure hyperthyroidism individuals. meanwhile, the investigators also intended to evaluate the morphological difference in effected skeletal muscles and investigate their relation with genetic variance.

chinese males of their third and forth decades are extremely predisposed to periodic paralysis when they are hyperthyroid. due to their imbalanced predilection to the disease, genetic variance is considered to be critical to the pathogenesis. in addition, since proximal limb skeletal muscles are the major sites of target, and they are also believed to play a role in the disease generation. thus, we intend to analyze the genetic and morphological variances between tpp patients and pure hyperthyroidism patients and simultaneously the relation between genetic variance and morphological difference. in this way, we hope to provide evidence for a better understanding of the disease.

Eligibility criteria:
inclusion criteria: a recent history(within three months) of acute limb muscle weakness, hypokalemia and decreased tsh with elevated free ft4, ft3. exclusion criteria: hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease,
time-dependent amiodarone treatment in atrial fibrillation

Conditions: Atrial Fibrillation

Summary: sixty consecutive emergency patients with newly diagnosed atrial fibrillation were randomized into two groups. the first received intravenous amiodarone infusions continuously for 24 hours; the second received amiodarone until sinus rhythms was reached or for up to 72 hours. the efficacy and safety of administering intravenous infusions of amiodarone for up to 72 hours were investigated and compared to the efficacy and safety of administering a standard 24 hours infusion of amiodarone. specifically, the use of up to 72 hours infusions was considered as a new strategy to improve rates of conversion to sinus rhythm without altering the safety profile of the drug.

an open randomized clinical trial was conducted that included 60 emergency adult patients who were candidates for drug cardioversion after first symptomatic episodes of af. the patients were randomized in equal proportions and sequentially placed in one of two treatment groups; no patient knew to which group he or she belonged. the first group received intravenous amiodarone infusions at doses of 5 mg/kg for over 30 min, followed by 20 mg/kg until 24 hours was reached. the second group received intravenous amiodarone infusions at doses of 5 mg/kg for over 30 min, followed by 20 mg/kg every 24 hours for up to 72 hours. all patients were continuously monitored using electrocardiograms, and echocardiograms were performed within 24 hours after the randomized trial began. the exact time of each patient's cardioversion was documented. in addition, general laboratory tests, lipid profiles, thyroid profiles and chest x-rays were obtained for all patients. a sample size of 30 subjects in each group was calculated. a conversion rate of 60% was assumed, according to literature, and an estimated increase to 90% was assumed for the experimental group to find differences with a power of 0.8 and an alpha error of 0.05. the primary goal was to obtain was a sinus rhythm conversion rate. the secondary goal was to obtain a combined complication rate by noting various complications in the patients, such as phlebitis, symptomatic hypotension that required vasopressors, bradycardia, nausea, vomiting and any organ embolism.

Eligibility criteria:
inclusion criteria: * ≥18 years old * emergency patients * first symptomatic episodes of atrial fibrillation exclusion criteria: * hemodynamic instability, * previous use of antiarrhythmic drugs * use of digoxin seven or fewer days prior to the study * active thyroid disease * known adverse reactions to amiodarone * other ventricular arrhythmias * contraindications for anticoagulation * acute renal failure * chronic liver disease * transaminase levels that were twice the normal levels * acute pulmonary edema * uncontrolled hypertension (\> 180/110 mmhg) * unstable angina * patients who were pregnant and/or breast feeding

Keywords: atrial fibrillation intravenous amiodarone drug safety profile chemical cardioversion